IL2 and neoplasm: Besides, patients not responding to high-dose IL-2 exhibited increased Treg cell expansion, which might promote tumor progression in turn.122 To address these limitations, new therapies are being designed to selectively enhance immune activation but avoid Treg accumulation and high IL-2 dosing.